Schnieders Capital Management’s iShares Biotechnology ETF IBB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | – | Sell |
-1,854
| Closed | -$270K | – | 215 |
|
|
2024
Q3 | $270K | Sell |
1,854
-67
| -3% | -$9.69K | 0.05% | 179 |
|
|
2024
Q2 | $264K | Sell |
1,921
-15
| -0.8% | -$2K | 0.05% | 166 |
|
|
2024
Q1 | $266K | Hold |
1,936
| – | – | 0.05% | 172 |
|
|
2023
Q4 | $263K | Sell |
1,936
-35
| -2% | -$4.27K | 0.06% | 171 |
|
|
2023
Q3 | $241K | Hold |
1,971
| – | – | 0.05% | 163 |
|
|
2023
Q2 | $250K | Hold |
1,971
| – | – | 0.05% | 171 |
|
|
2023
Q1 | $255K | Hold |
1,971
| – | – | 0.06% | 172 |
|
|
2022
Q4 | $259K | Sell |
1,971
-100
| -5% | -$12.9K | 0.06% | 176 |
|
|
2022
Q3 | $242K | Sell |
2,071
-100
| -5% | -$12.4K | 0.06% | 171 |
|
|
2022
Q2 | $255K | Buy |
2,171
+25
| +1% | +$2.97K | 0.08% | 158 |
|
|
2022
Q1 | $280K | Buy |
2,146
+771
| +56% | +$100K | 0.07% | 168 |
|
|
2021
Q4 | $210K | Buy |
1,375
+95
| +7% | +$14.7K | 0.05% | 196 |
|
|
2021
Q3 | $207K | Hold |
1,280
| – | – | 0.06% | 184 |
|
|
2021
Q2 | $210K | Sell |
1,280
-176
| -12% | -$27.1K | 0.06% | 177 |
|
|
2021
Q1 | $219K | Buy |
+1,456
| New | +$231K | 0.07% | 169 |
|
|
2020
Q1 | – | Sell |
-1,762
| Closed | -$212K | – | 160 |
|
|
2019
Q4 | $212K | Buy |
+1,762
| New | +$197K | 0.08% | 168 |
|
|
2019
Q3 | – | Sell |
-3,172
| Closed | -$346K | – | 164 |
|
|
2019
Q2 | $346K | Sell |
3,172
-220
| -6% | -$23.4K | 0.14% | 115 |
|
|
2019
Q1 | $379K | Sell |
3,392
-35
| -1% | -$3.84K | 0.16% | 102 |
|
|
2018
Q4 | $330K | Sell |
3,427
-568
| -14% | -$60.3K | 0.16% | 101 |
|
|
2018
Q3 | $487K | Buy |
3,995
+110
| +3% | +$13K | 0.2% | 97 |
|
|
2018
Q2 | $427K | Buy |
3,885
+270
| +7% | +$28.9K | 0.18% | 101 |
|
|
2018
Q1 | $386K | Sell |
3,615
-145
| -4% | -$16.1K | 0.17% | 109 |
|
|
2017
Q4 | $402K | Buy |
3,760
+250
| +7% | +$26.7K | 0.17% | 109 |
|
|
2017
Q3 | $390K | Buy |
3,510
+1,050
| +43% | +$112K | 0.17% | 107 |
|
|
2017
Q2 | $254K | Buy |
2,460
+225
| +10% | +$22.2K | 0.12% | 133 |
|
|
2017
Q1 | $218K | Buy |
+2,235
| New | +$214K | 0.1% | 138 |
|
|
2016
Q4 | – | Sell |
-2,175
| Closed | -$210K | – | 147 |
|
|
2016
Q3 | $210K | Sell |
2,175
-1,395
| -39% | -$133K | 0.12% | 130 |
|
|
2016
Q2 | $306K | Buy |
3,570
+762
| +27% | +$68.4K | 0.17% | 111 |
|
|
2016
Q1 | $244K | Buy |
+2,808
| New | +$251K | 0.14% | 115 |
|
Other funds holding IBB
Schnieders Capital Management's IBB Position: Q4 2024 in Review
Schnieders Capital Management sold out of iShares Biotechnology ETF (IBB) in Q4 2024, closing a stake of 1,854 shares — an estimated $270K sold.
Schnieders Capital Management first reported a position in IBB in Q1 2016 and held it in 29 quarters. The position peaked at $487K in Q3 2018. 874 funds tracked by Wall St. Rank hold IBB as of Q4 2024.
- Schnieders Capital Management reported no remaining iShares Biotechnology ETF position as of Q4 2024 after selling out during the quarter.
- Schnieders Capital Management sold 1,854 iShares Biotechnology ETF shares in Q4 2024, an estimated $270K.
- Schnieders Capital Management first reported a position in iShares Biotechnology ETF in Q1 2016 and held it in 29 quarters.
- Schnieders Capital Management's iShares Biotechnology ETF position peaked at $487K in Q3 2018.
- 874 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q4 2024.
Based on Schnieders Capital Management's 13F filing for Q4 2024, filed 5 Feb 2025.